Back to Journals » Vascular Health and Risk Management » Volume 10

Dabigatran and myocardial infarction: a foggy scenario

Authors Pontillo D, Patruno N

Received 13 November 2013

Accepted for publication 19 November 2013

Published 20 January 2014 Volume 2014:10 Pages 45—48

DOI https://doi.org/10.2147/VHRM.S57529

Checked for plagiarism Yes


Daniele Pontillo,1 Nicolino Patruno2

1Division of Cardiology, Hospital Complex Belcolle, Pavilion Montefiascone Montefiascone, Italy; 2Division of Cardiology, San Giuseppe Hospital, Albano Laziale (RM), Italy

The pooled analysis from Clemens et al1 furnishes an up-to-date contribution on the scenario of the risk of myocardial infarction (MI) of patients on dabigatran in any disease setting, formulating a "non-guilty" sentence in favor of dabigatran in terms of net clinical benefit, even though the authors did find an absolute increase in MIs. We believe that this contribution may represent further evidence favoring the overall efficacy of dabigatran, in agreement with data from Hohnloser et al2 who analyzed the cardiovascular (CV) ischemic outcomes from the RE-LY (Randomized Evaluation of Long-term anticoagulant therapy) study and finding no statistically significant difference of MI between dabigatran and the comparison treatment, and with those from Dans et al3 who considered solely CV mortality with no further discrimination. Essentially, this represents the leitmotif of the last three years after the revised adjudication of cardiovascular events in the RE-LY study4 with a non-significant increase in MIs with dabigatran at any dose (for 150 mg twice a day, relative risk 1.27, 0.94–1.71, P=0.12).

View original paper by Clemens and colleagues.

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]